Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

HIV Infection

Free Subscription Articles published in Vaccine Retrieve available abstracts of 108 articles: HTML format Text format

Single Articles

January 2012
1. ZHOU M , Kostoula I, Brill B, Panou E, et al
   Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice.
   Vaccine. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
2. GAFFGA NH , Flagg EW, Weinstock HS, Shlay JC, et al
   Monitoring HPV type-specific prevalence over time through clinic-based surveillance: A perspective on vaccine effectiveness.
   Vaccine. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
3. LIAO Q , Strong AJ, Liu Y, Liu Y, et al
   HIV vaccine candidates generate in vitro T cell response to putative epitopes in Chinese-origin rhesus macaques.
   Vaccine. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
4. COX JH , Ferrari MG, Earl P, Lane JR, et al
   Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.
   Vaccine. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   December 2011
5. NOSSAL GJ
   Vaccines of the future.
   Vaccine. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
6. TANG J , Yin R, Tian Y, Huang Z, et al
   A novel self-assembled nanoparticle vaccine with HIV-1 Tat(49-57)/HPV16 E7(49-57) fusion peptide and GM-CSF DNA elicits potent and prolonged CD8(+) T cell-dependent anti-tumor immunity in mice.
   Vaccine. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. LAI L , Kwa SF, Kozlowski PA, Montefiori DC, et al
   SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses.
   Vaccine. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. HAKIM H , Allison KJ, Van De Velde LA, Li Y, et al
   Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.
   Vaccine. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
9. KANAGAVELU SK , Snarsky V, Termini JM, Gupta S, et al
   Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.
   Vaccine. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
10. AHMED FK , Clark BE, Burton DR, Pantophlet R, et al
    An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2011
11. KAUFMAN DR , Li F, Cruz AN, Self SG, et al
    Focus and breadth of cellular immune responses elicited by a heterologous insert prime-boost vaccine regimen in rhesus monkeys.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
12. VON GOTTBERG A , Cohen C, Whitelaw A, Chhagan M, et al
    Invasive disease due to Haemophilus influenzae serotype b ten years after routine vaccination, South Africa, 2003-2009.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
13. ALI TABEI SM , Li Y, Weigert M, Dinner AR, et al
    Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. KOFF WC
    HIV vaccine development: Challenges and opportunities towards a solution of the HIV vaccine-neutralizing antibody problem.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
15. PARIS R , Bejrachandra S, Thongcharoen P, Nitayaphan S, et al
    HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX((R)) B/E.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
16. ZAHARATOS GJ , Yu J, Pace C, Song Y, et al
    HIV-1 and influenza antigens synthetically linked to IgG2a Fc elicit superior humoral responses compared to unmodified antigens in mice.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2011
17. SUI Y , Gagnon S, Dzutsev A, Zhu Q, et al
    TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4(+) memory T cell loss in SIVmac251-challenged rhesus macaques.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. BIALUK I , Whitney S, Andresen V, Florese RH, et al
    Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. PALLIKKUTH S , Rogers K, Villinger F, Dosterii M, et al
    Interleukin-21 administration to rhesus macaques chronically infected with simian immunodeficiency virus increases cytotoxic effector molecules in T cells and NK cells and enhances B cell function without increasing immune activation or viral replicat
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
20. HATAKEYAMA S , Iwatsuki-Horimoto K, Okamoto K, Nukui Y, et al
    Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
21. PARIANI E , Boschini A, Amendola A, Poletti R, et al
    Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2011
22. NYBLADE L , Singh S, Ashburn K, Brady L, et al
    "Once I begin to participate, people will run away from me": Understanding stigma as a barrier to HIV vaccine research participation in Kenya.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. KUMAR R , Tuen M, Li H, Tse DB, et al
    Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. WANG J , Xu L, Tong P, Chen YH, et al
    Mucosal antibodies induced by tandem repeat of 2F5 epitope block transcytosis of HIV-1.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
25. WINNOCK M , Bani-Sadr F, Pambrun E, Loko MA, et al
    Prevalence of immunity to hepatitis viruses A and B in a large cohort of HIV/HCV-coinfected patients, and factors associated with HAV and HBV vaccination.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
26. GARCIA F , Bernaldo de Quiros JC, Gomez CE, Perdiguero B, et al
    Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. PHONGSAMART W , Sirisanthana V, Wittawatmongkol O, Maleesatharn A, et al
    Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-infected Thai children.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2011
28. TOUSSAINT NC , Maman Y, Kohlbacher O, Louzoun Y, et al
    Universal peptide vaccines - Optimal peptide vaccine design based on viral sequence conservation.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. COOPER C , Thorne A
    Influenza vaccine Oculorespiratory syndrome incidence is reduced in HIV.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. BAKARI M , Aboud S, Nilsson C, Francis J, et al
    Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
31. GABITZSCH ES , Xu Y, Balint JP Jr, Balcaitis S, et al
    Induction and comparison of SIV immunity in Ad5 naive and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
32. WEST NP , Thomson SA, Triccas JA, Medveczky CJ, et al
    Delivery of a multivalent scrambled antigen vaccine induces broad spectrum immunity and protection against tuberculosis.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
33. VOJNOV L , Bean AT, Peterson EJ, Chiuchiolo MJ, et al
    DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4(+) T cells, but few subdominant epitope-specific CD8(+) T cells.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
34. LAU CY , Swann EM, Singh S, Kafaar Z, et al
    Conceptual framework for behavioral and social science in HIV vaccine clinical research.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
35. CHESSON HW , Ekwueme DU, Saraiya M, Dunne EF, et al
    The cost-effectiveness of male HPV vaccination in the United States.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. FRATERNALE A , Paoletti MF, Dominici S, Buondelmonte C, et al
    Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
37. YUAN T , Li J, Zhang Y, Wang Y, et al
    Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: Differences from the human counterparts and implications for HIV-1 vaccine development.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
38. DOMM W , Brooks L, Chung HL, Feng C, et al
    Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: Association with mucoadhesion and efficient penetration of the sublingual barrier.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. GARCIA F , Routy JP
    Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. LU PJ , Byrd KK, Murphy TV, Weinbaum C, et al
    Hepatitis B vaccination coverage among high-risk adults 18-49 years, U.S., 2009.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
41. FOMSGAARD A , Karlsson I, Gram G, Schou C, et al
    Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
42. HANKINS CA , Glasser JW, Chen RT
    Modeling the impact of RV144-like vaccines on HIV transmission.
    Vaccine. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
43. CHEN RT , Hu DJ, Dunne E, Shaw M, et al
    Preparing for the availability of a partially effective HIV vaccine: Lessons from other licensed vaccines.
    Vaccine. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
44. OKIKE IO , Yung C, Ladhani S, Oeser C, et al
    The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
45. DHALLA S , Poole G
    Barriers of enrolment in HIV vaccine trials: A review of HIV vaccine preparedness studies.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
46. ANDERSSON KM , Paltiel AD, Owens DK
    The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial results.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
47. THANEE C , Pancharoen C, Likitnukul S, Luangwedchakarn V, et al
    The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2011
48. SCHNEIDER K , Kerr CC, Hoare A, Wilson DP, et al
    Expected epidemiological impacts of introducing an HIV vaccine in Thailand: A model-based analysis.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
49. FREW PM , Archibald M, Hixson B, Del Rio C, et al
    Socioecological influences on community involvement in HIV vaccine research.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
50. GIRARD MP , Osmanov S, Assossou OM, Kieny MP, et al
    Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: A review.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
51. NAGELKERKE NJ , Hontelez JA, de Vlas SJ
    The potential impact of an HIV vaccine with limited protection on HIV incidence in Thailand: A modeling study.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
52. GHUNAIM H , Kumar A, Torres J, Diaz-Mitoma F, et al
    An immunological comparison between lipidated and non-lipidated multivalent HIV-1 peptides representing Gp120 and Gag hypervariable regions.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
53. SIRIVICHAYAKUL S , Thantiworasit P, Chatkulkawin P, Buranapraditkun S, et al
    Immunogenicity assay validation for an HIV vaccine trial: High IFNgamma(+)/IL-2(+) CD8(+) T cells background in healthy Thais.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
54. DEMBERG T , Ettinger AA, Aladi S, McKinnon K, et al
    Strong viremia control in vaccinated macaques does not prevent gradual Th17 cell loss from central memory.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
55. VOYTEK CD , Jones KT, Metzger DS
    Selectively willing and conditionally able: HIV vaccine trial participation among women at "high risk" of HIV infection.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
56. ANDERSSON KM , Stover J
    The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
57. HONTELEZ JA , Nagelkerke N, Barnighausen T, Bakker R, et al
    The potential impact of RV144-like vaccines in rural South Africa: A study using the STDSIM microsimulation model.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
58. GRAY RT , Ghaus MH, Hoare A, Wilson DP, et al
    Expected epidemiological impact of the introduction of a partially effective HIV vaccine among men who have sex with men in Australia.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
59. COTTE L , Voirin N, Richard C, Brochier C, et al
    Factors associated with pandemic influenza A/H1N1 vaccine coverage in a French cohort of HIV-infected patients.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
60. MATOBA N , Shah NR, Mor TS
    Humoral immunogenicity of an HIV-1 envelope residue 649-684 membrane-proximal region peptide fused to the plague antigen F1-V.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
61. LAKHASHE SK , Velu V, Sciaranghella G, Siddappa NB, et al
    Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: Efficacy against repeated mucosal R5 clade C SHIV challenges.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
62. YANAGISAWA N , Kazuhiro M, Ajisawa A, Imamura A, et al
    Reduced immune response to influenza A (H1N1) 2009 monovalent vaccine in HIV-infected Japanese subjects.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
63. GIL C , Climent N, Garcia F, Hurtado C, et al
    Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
64. YAN J , Corbitt N, Pankhong P, Shin T, et al
    Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
65. PILLAI VK , Kannanganat S, Penaloza-Macmaster P, Chennareddi L, et al
    Different patterns of expansion, contraction and memory differentiation of HIV-1 Gag-specific CD8 T cells elicited by adenovirus type 5 and modified vaccinia Ankara vaccines.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
66. MATYAS GR , Alving CR
    Antigen-specific enhancement of natural human IgG antibodies to phosphatidylcholine, phosphatidylglycerol, phosphatidylinositol-4-phosphate, cholesterol, and lipid A by a liposomal vaccine containing lipid A.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
67. BAROUCH DH , Kik SV, Weverling GJ, Dilan R, et al
    International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
68. SANCHEZ-PALOMINO S , Massanella M, Carrillo J, Garcia A, et al
    A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
69. CHARLES-NINO C , Pedroza-Roldan C, Viveros M, Gevorkian G, et al
    Variable epitope libraries: New vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
70. TAGLIAMONTE M , Visciano ML, Tornesello ML, De Stradis A, et al
    HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
71. VISCIANO ML , Diomede L, Tagliamonte M, Tornesello ML, et al
    Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
72. MALASPINA A , Rinaldo CR, Sekaly RP, Flores J, et al
    "In vitro systems to characterize the immune response to HIV-1 and HIV-1 vaccine candidates", NIAID Workshop Report, Bethesda, August 4, 2010.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
73. SAKSAWAD R , Likitnukul S, Warachit B, Hanvivatvong O, et al
    Immunogenicity and safety of a pediatric dose virosomal hepatitis A vaccine in Thai HIV-infected children.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
74. LIARD C , Munier S, Arias M, Joulin-Giet A, et al
    Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
75. SAMPSON SL , Mansfield KG, Carville A, Magee DM, et al
    Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
76. THOMAS RE , Lorenzetti DL, Spragins W, Jackson D, et al
    Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: Systematic review.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2011
77. DONNELLY L , Curran RM, Tregoning JS, McKay PF, et al
    Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms.
    Vaccine. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
78. LONG EF , Owens DK
    The cost-effectiveness of a modestly effective HIV vaccine in the United States.
    Vaccine. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
79. CLARK K , Cavicchi J, Jensen K, Fitzgerald R, et al
    Patent data mining: A tool for accelerating HIV vaccine innovation.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
80. LAO-ARAYA M , Puthanakit T, Aurpibul L, Taecharoenkul S, et al
    Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
81. PARIS RM
    Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148).
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
82. PANDOLFI E , Carloni E, Marino MG, Ciofi Degli Atti ML, et al
    Immunization coverage and timeliness of vaccination in Italian children with chronic diseases.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
83. NANJUNDAPPA RH , Wang R, Xie Y, Umeshappa CS, et al
    GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4(+) T-independent CTL responses.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
84. ANTHONY DD , Umbleja T, Aberg JA, Kang M, et al
    Lower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individuals.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
85. BROCCA-COFANO E , McKinnon K, Demberg T, Venzon D, et al
    Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
86. SISTIGU A , Bracci L, Valentini M, Proietti E, et al
    Strong CD8(+) T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
87. MARTHAS ML , Van Rompay KK, Abbott Z, Earl P, et al
    Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
88. CRUM-CIANFLONE NF , Iverson E, Defang G, Blair PJ, et al
    Durability of antibody responses after receipt of the monovalent 2009 influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
89. BYRD KK , Santibanez TA, Chaves SS
    Predictors of hepatitis A vaccination among young children in the United States.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
90. RANASINGHE C , Eyers F, Stambas J, Boyle DB, et al
    A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
91. STERMOLE BM , Grandits GA, Roediger MP, Clark BM, et al
    Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
92. KOSALARAKSA P , Srirompotong U, Newman RW, Lumbiganon P, et al
    Serological response to trivalent inactive influenza vaccine in HIV-infected children with different immunologic status.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
93. FABBIANI M , Di Giambenedetto S, Sali M, Farina S, et al
    Immune response to influenza A (H1N1) monovalent MF59-adjuvanted vaccine in HIV-infected patients.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
94. FERRANTELLI F , Maggiorella MT, Schiavoni I, Sernicola L, et al
    A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
95. BUNUPURADAH T , Ananworanich J, Pancharoen C, Petoumenos K, et al
    Randomized study of intradermal compared to intramuscular hepatitis B vaccination in HIV-infected children without severe immunosuppression.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
96. LAU CY , Swann EM, Singh S
    Behavioral and social science in HIV vaccine clinical research: Workshop report.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
97. MATTIACIO J , Walter S, Brewer M, Domm W, et al
    Dense display of HIV-1 envelope spikes on the lambda phage scaffold does not result in the generation of improved antibody responses to HIV-1 Env.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
98. GUDMUNDSDOTTER L , Wahren B, Haller BK, Boberg A, et al
    Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2011
99. LIU Y , Li F, Liu Y, Hong K, et al
    HIV fragment gag vaccine induces broader T cell response in mice.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
100. STRBO N , Vaccari M, Pahwa S, Kolber MA, et al
     Gp96(SIV)Ig immunization induces potent polyepitope specific, multifunctional memory responses in rectal and vaginal mucosa.
     Vaccine. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
101. YU M , Vajdy M
     A novel retinoic acid, catechin hydrate and mustard oil-based emulsion for enhanced cytokine and antibody responses against multiple strains of HIV-1 following mucosal and systemic vaccinations.
     Vaccine. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
102. JIN F , Stein AN, Conway EL, Regan D, et al
     Trends in anal cancer in Australia, 1982-2005.
     Vaccine. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
103. ETCHEVERRY MF , Lum PJ, Evans JL, Sanchez E, et al
     HIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco.
     Vaccine. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
104. NIU L , Termini JM, Kanagavelu SK, Gupta S, et al
     Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes.
     Vaccine. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
105. AGARWAL A , Hioe CE, Swetnam J, Zolla-Pazner S, et al
     Quantitative assessment of masking of neutralization epitopes in HIV-1.
     Vaccine. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
106. KEEFER MC , Frey SE, Elizaga M, Metch B, et al
     A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.
     Vaccine. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
107. PALMA P , Romiti ML, Li Pira G, Montesano C, et al
     The PEDVAC trial: Preliminary data from the first therapeutic DNA vaccination in HIV-infected children.
     Vaccine. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
108. KITYO C , Bousheri S, Akao J, Ssali F, et al
     Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: A Phase I safety study.
     Vaccine. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     

Thank you for your interest in scientific medicine.

This service is provided by AMEDEO through an unrestricted educational grant from Boehringer Ingelheim.

Amedeo is a Flying Publisher website.    Design: